Tesamorelin in Mexico — guide and where to buy

Introduction

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH) with one of the more characterized evidence bases among peptides related to growth-hormone secretion. In the Mexican research peptide market, its availability is more recent than that of more established compounds, which makes it more important to distinguish between suppliers with analytical documentation and resellers without it.

This guide describes the structure of the compound, the nature of the available evidence, handling considerations for a receiving laboratory, and concrete steps to evaluate a vial on receipt. The focus is strictly technical and research-oriented.

What is tesamorelin

Tesamorelin is a synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH), stabilized against enzymatic degradation. It acts at the pituitary GHRH receptor to stimulate endogenous growth-hormone secretion. Its CAS number is 218949-48-5.

The structural modification that stabilizes it against enzymes prolongs its relative half-life compared with native GHRH. In the literature, tesamorelin has been characterized preclinically and clinically chiefly for its association with the preferential reduction of visceral adipose tissue. Its molecular weight is approximately 5,135.86 Da, a value relevant for identity confirmation by mass spectrometry.

Preclinical evidence

Evidence on tesamorelin includes preclinical models and clinical trials in specific indications. The most-cited reference study, published by Falutz and colleagues, evaluated the metabolic effects of a growth-hormone-releasing factor in patients and described the preferential reduction of visceral adipose tissue ^[1].

• Stimulation of the pituitary GHRH receptor and endogenous growth-hormone secretion ^[1].
• Association with the preferential reduction of visceral adipose tissue in the published characterization ^[1].
• Structural stabilization against enzymatic degradation relative to native GHRH.
• In vitro studies of GHRH-receptor binding.

The primary reference is Falutz J, Allas S, Blot K, et al. «Metabolic effects of a growth hormone–releasing factor in patients with HIV.» N Engl J Med. 2007;357(23):2359–2370 ^[1], available on PubMed (https://pubmed.ncbi.nlm.nih.gov/18057335/). Tesamorelin's regulatory status varies by jurisdiction and indication; as research material, its distribution and use must remain within the authorized scientific research framework.

Research considerations

For a laboratory incorporating tesamorelin into a protocol, operational considerations include presentation form, storage conditions, and study design. The standard presentation is sterile lyophilized in borosilicate vials. Because it is a long 44-amino-acid peptide, the integrity of the lyophilizate and the stability of the reconstituted solution require particular attention, and reconstitution is performed with the diluent defined in the lab SOP, usually bacteriostatic water.

• Store the lyophilized vial at −20 °C, protected from light and moisture.
• Reconstitute with sterile bacteriostatic water per the institutional SOP.
• Keep the compound in lyophilized form until the moment of use.
• Protect from light to limit peptide degradation.
• Aliquot the reconstituted solution to avoid repeated thermal cycles.

Study design must comply with applicable animal ethics protocols (NOM-062-ZOO-1999 in Mexico) and be authorized by the institutional committee. Use outside an authorized protocol does not fall within the scientific research framework.

How to evaluate a vial

Evaluating a tesamorelin vial on receipt follows the same criteria as any research peptide, with emphasis on analytical traceability. HPLC purity stated in the COA must be ≥99%, with the chromatogram of the specific lot. Identity by mass spectrometry must show an observed mass consistent with the theoretical molecular weight of the 44-amino-acid analog (approximately 5,135.86 Da).

1. Verify the COA corresponds to the physical lot of the vial received.
2. Confirm HPLC purity ≥99% with attached chromatogram.
3. Confirm identity by MS: observed mass vs. theoretical mass.
4. Review batch traceability from synthesis to the final vial.
5. Inspect the lyophilizate: uniform solid, no particles or moisture.

MX-1 Labs distributes tesamorelin as a research compound from CDMX, with per-batch COA and MS-confirmed identity; the per-batch retention sample is held by the synthesizing lab. For a Mexican laboratory, this combination of analytical documentation and domestic origin simplifies audits and reduces transit times.

Conclusion

Tesamorelin is a GHRH analog with preclinical and clinical characterization in specific indications, but its distribution as research material does not imply an approved use outside that framework. Its incorporation into a protocol requires robust analytical documentation from the supplier, handling conditions defined in the SOP, and an experimental design authorized by the institutional committee. Supplier choice must rest on verifiable criteria, not commercial messaging.

This article is educational only. Tesamorelin is not a medication or a product for human consumption and is distributed solely as a material for research use only in the laboratory.